Zai Lab Ltd. Enhances Patient Access with Inclusion in China’s National Reimbursement Drug List

Zai Lab Expands Patient Access with Inclusion in National Reimbursement Drug List

Zai Lab Limited announces a significant milestone in its commitment to enhancing patient access to innovative therapies, with several of its medicines now part of the 2024 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA). Among the highlighted treatments is AUGTYRO® (repotrectinib), which is now available for adult patients diagnosed with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). This inclusion is particularly crucial given the alarming statistics surrounding lung cancer in China, where NSCLC represents approximately 85% of the 1,060,600 new cases reported in 2022. The addition of AUGTYRO® not only broadens treatment options but also significantly improves the affordability and accessibility of this promising therapy for a patient demographic that faces dire health challenges.

The NRDL inclusion also sees the renewal of NUZYRA® (omadacycline) for the intravenous treatment of adults suffering from community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). This renewal underscores Zai Lab's ongoing commitment to providing effective solutions for common yet serious infections, thereby addressing a critical area of public health. Furthermore, QINLOCK® (ripretinib) remains a key option for patients with advanced gastrointestinal stromal tumors (GIST) who have previously undergone treatment with three or more kinase inhibitors. The presence of these medicines in the NRDL reflects the company's strategic focus on addressing significant unmet medical needs in the region.

Chief Commercial Officer Andrew Zhu expresses optimism regarding the launch of AUGTYRO® by the end of 2024, highlighting its potential to improve treatment durability for patients with ROS1+ NSCLC. With this inclusion, Zai Lab now boasts six products in the NRDL, enhancing its portfolio while reinforcing its commitment to innovative therapy access across China. The company’s efforts align with the broader goal of improving patient lives in a region grappling with high lung cancer mortality rates and a pressing need for effective treatment options.

Zai Lab's inclusion in the NRDL marks a pivotal development in its strategic initiatives, amplifying its role in the Chinese healthcare landscape. The company continues to navigate the complexities of the market while ensuring that patients have access to critical therapies that can transform their treatment journeys. As Zai Lab moves forward, it remains dedicated to bridging the gap between groundbreaking medical innovations and the patients who need them most.